Literature DB >> 2443587

In situ identification of activated Ta1+ T lymphocytes in human leprosy skin lesions.

J Y Shen1, F M Hofman, J R Gunter, R L Modlin, T H Rea.   

Abstract

Using a monoclonal antibody, anti-Ta1, that identifies antigen-activated T lymphocytes in vitro, we sought to identify activated T lymphocytes in leprosy skin lesions. Greater numbers of Ta1 positive T lymphocytes were observed in tuberculoid leprosy, lepromin skin tests, and reversal reactions as compared with lepromatous leprosy or erythema nodosum leprosum (ENL) (p less than 0.001). With a double-staining technique, we found that the majority of these activated T lymphocytes were of the helper/inducer phenotype. No differences of Ta1 positive lymphocytes were observed in the peripheral blood. The defective cell-mediated immune response in lepromatous and ENL patients correlates with, and may be related to the failure of T-helper/inducer activation or proliferation in the presence of Mycobacterium leprae.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443587

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  4 in total

Review 1.  Immunopathology of leprosy granulomas.

Authors:  R L Modlin; T H Rea
Journal:  Springer Semin Immunopathol       Date:  1988

2.  Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups.

Authors:  F W Miller; L A Love; S A Barbieri; J E Balow; P H Plotz
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

3.  Immunohistology of tuberculous adenitis in symptomatic HIV infection.

Authors:  J Y Shen; P F Barnes; T H Rea; P R Meyer
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

Review 4.  A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum.

Authors:  Anastasia Polycarpou; Stephen L Walker; Diana N J Lockwood
Journal:  Front Immunol       Date:  2017-03-13       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.